|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2602-2603.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Comment on Sorror et al, page 2912
HCT outcomes: a new tool?
Roy B. Jones
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER
Chronic disease comorbidities of patients undergoing hematopoietic cell allotransplantation are important prognostic determinants of survival and overall outcome.
The diversity of hematopoietic cell transplantation (HCT) options has never been greater, allowing a larger spectrum of patients to be treated while at the same time challenging transplantation physicians to more accurately assess the quality of HCT outcomes. As older patients with a variety of coexisting medical conditions ("comorbidities") undergo nonmyeloablative HCT, it is important to assess the impact of these comorbidities on survival and cure. The Charlson Comorbidity Index (CCI) was developed to estimate mortality risk for patients with multiple chronic medical conditions1 and is widely used in patients with solid tumors and other potentially fatal diseases. Sorror and colleagues tested the CCI in patients with hematologic malignancies undergoing allogeneic HCT.2,3 They found that only 12% of Seattle patients had elevated scores prior to HCT, so the CCI lacked the discrimination necessary to separate groups with varying risk. In this issue of Blood, the same group describes the development and testing of an HCT-specific comorbidity index with higher discriminative capacity. The correlation of index scores with survival following transplantation was markedly superior to the CCI. Pretransplantation score assignment should be simple to accomplish using the new system, and be highly objective.
View larger version (29K):
[in this window]
[in a new window]
|
Kaplan-Meier estimates of survival as stratified by the new HCT-CI compared with the original CCI among patients of the validation set. See the complete figure in the article beginning on page 2912.
|
|
This new comorbidity scoring system raises new questions and provides new opportunities. Is the index reproducible in multiple centers? Is it applicable to autotransplantations? Can the index be used to better direct patients to either myeloablative or nonmyeloablative allotransplant strategies? Can the index be added to other established prognostic variables to better predict patient outcome? As expectations from insurers, government agencies, and patients that transplantation outcomes become more quantifiable and predictable increase, this new index could add an important tool to assist in this effort. Finally, this index might allow refinement of our estimates of the outcomes of newly reported research treatments. Reporting comorbidity data of the type used in this index will likely become as important as defining cancer diagnosis, disease stage, remission status, and other, more familiar prognostic variables. 
References
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-383.[CrossRef][Medline]
[Order article via Infotrieve]
- Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HL-A-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood. 2004;104: 961-968.[Abstract/Free Full Text]
- Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104: 1550-1558.[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
- Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frederic Baron, Brenda M. Sandmaier, David G. Maloney, and Barry Storer
Blood 2005 106: 2912-2919.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Blood,
December 15, 2007;
110(13):
4606 - 4613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
